Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) – Equities research analysts at Jefferies Financial Group issued their Q1 2023 EPS estimates for Karyopharm Therapeutics in a research note issued to investors on Wednesday, February 1st. Jefferies Financial Group analyst M. Raycroft forecasts that the company will post earnings of ($0.30) per share for the quarter. The consensus estimate for Karyopharm Therapeutics' current full-year earnings is ($1.93) per share.

Several other analysts have also recently issued reports on the company. Piper Sandler initiated coverage on Karyopharm Therapeutics in a report on Thursday, January 19th. They issued an "overweight" rating and a $8.00 target price for the company. Royal Bank of Canada upgraded shares of Karyopharm Therapeutics from a "sector perform" rating to an "outperform" rating and raised their price objective for the stock from $7.00 to $10.00 in a research report on Friday, November 4th. SVB Leerink reduced their target price on shares of Karyopharm Therapeutics from $6.00 to $5.00 and set a "market perform" rating on the stock in a research note on Tuesday, January 10th. Morgan Stanley dropped their price target on shares of Karyopharm Therapeutics from $7.00 to $5.00 and set an "equal weight" rating for the company in a research note on Friday, January 27th. Finally, HC Wainwright reduced their price target on shares of Karyopharm Therapeutics from $18.00 to $16.00 and set a "buy" rating on the stock in a research report on Tuesday, January 10th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $9.33.

Karyopharm Therapeutics Price Performance

Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) last released its earnings results on Thursday, November 3rd. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.11. The business had revenue of $36.15 million during the quarter, compared to analysts' expectations of $34.82 million.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several large investors have recently made changes to their positions in the stock. State Street Corp raised its position in Karyopharm Therapeutics by 98.9% in the first quarter. State Street Corp now owns 10,966,701 shares of the company's stock valued at $80,825,000 after purchasing an additional 5,453,021 shares during the period. Walleye Capital LLC raised its holdings in shares of Karyopharm Therapeutics by 2,000.9% in the 2nd quarter. Walleye Capital LLC now owns 1,745,415 shares of the company's stock valued at $7,872,000 after buying an additional 1,662,337 shares during the period. Bank of America Corp DE lifted its stake in Karyopharm Therapeutics by 338.0% during the 1st quarter. Bank of America Corp DE now owns 1,116,230 shares of the company's stock worth $8,227,000 after acquiring an additional 861,362 shares in the last quarter. ExodusPoint Capital Management LP boosted its holdings in Karyopharm Therapeutics by 3,215.0% during the 2nd quarter. ExodusPoint Capital Management LP now owns 645,985 shares of the company's stock valued at $2,913,000 after acquiring an additional 626,498 shares during the period. Finally, Vanguard Group Inc. grew its position in Karyopharm Therapeutics by 17.9% in the 1st quarter. Vanguard Group Inc. now owns 3,960,708 shares of the company's stock valued at $29,190,000 after acquiring an additional 601,901 shares in the last quarter. 96.13% of the stock is currently owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

(Get Rating)

Karyopharm Therapeutics, Inc is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).

Recommended Stories

• Get a free copy of the StockNews.com research report on Karyopharm Therapeutics (KPTI)
• Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
• Zimmer Biomet Beats on Earnings, Growth May be Priced In
• AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
• Ford Stock Going Forward After Big Earnings Flop
• Insiders And Institutions Buy Wolverine Worldwide

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.